Showing 4511-4520 of 5627 results for "".
- FDA Outlines Faster Path for COVID-19 Vaccines That Tackle New Variantshttps://modernod.com/news/fda-outlines-faster-path-for-covid-19-vaccines-that-tackle-new-variants/2478898/The FDA on Monday issued new guidance confirming that drugmakers will not have to perform large-scale trials for new COVID-19 vaccines or booster shots developed to combat new variants of SARS-CoV-2. “At this time, available information suggests that the FDA-authorized vaccines remain effec
- LumiThera Completes Patient Enrollment in LIGHTSITE III Clinical Study to Treat Dry AMDhttps://modernod.com/news/lumithera-completes-patient-enrollment-in-the-lightsite-iii-clinical-study-to-treat-dry-amd/2478882/LumiThera announced it has completed enrollment in its multicenter US clinical study in non-neovascular (dry) age-related macular degeneration (AMD) patients. The randomized, multicenter study, LIGHTSITE III, enrolled the last patient at the Byers Eye Insti
- New World Medical’s Next-Generation KDB GLIDE Now Commercially Availablehttps://modernod.com/news/new-world-medicals-next-generation-kdb-glide-now-commercially-available/2478880/New World Medical announced the launch of the KDB GLIDE device for advanced excisional goniotomy treatment of glaucoma. The KDB GLIDE, which was registered with the FDA in October 2020, is now commercially available to ophthalmic surgeons across the US looking for refined, precise performance dur
- LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-positive-interim-data-in-visual-and-erg-clinical-outcomes-in-the-electrolight-pilot-study-in-dry-amd-patients/2478872/LumiThera announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients. A total of 23 eyes from 15 subjects with intermediate dry AMD were enrolled into the prospective clinical study and treated with PBM using the Valeda Light Delivery System (3 times per week for 3 we
- Regenxbio Announces Additional Positive Interim Phase 1/2a and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-and-long-term-follow-up-data-of-rgx-314-for-the-treatment-of-wet-amd/2478873/Regenxbio reported additional positive interim data from Cohorts 4 and 5 of its RGX-314 phase 1/2a trial for the treatment of wet age-related macular degeneration (AMD), and Cohort 3 of its Long-Term Follow-Up (LTFU) study. RGX-314 is a potential best-in-class, one-time gene therapy for the treat
- Inspecs Launches Sustainable Botaniq Eyewear Collectionhttps://modernod.com/news/inspecs-launches-sustainable-botaniq-eyewear-collection/2478870/Inspecs has launched its own sustainable eyewear range called Botaniq. The Botaniq collection, which will initially launch with 48 SKUs across 16 styles, is designed by a team of in-house technical experts at Inspecs, using biodegradeable eyewear materials as a direct response to consumer demand
- GenSight Biologics Announces Publication of Results from Lumevoq Phase 1/2a Clinical Trial REVEAL in BioDrugshttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-phase-1-2a-clinical-trial-reveal-in-biodrugs/2478868/GenSight Biologics announced that the journal BioDrugs has published results from REVEAL, the phase 1/2a clinical trial that evaluated the safety of Lumevoq gene therapy in subjects with ND4 Leber Hereditary Optic Neuropathy (LHON) and determined the dose subsequently used in the ph
- Gyroscope Therapeutics Announces Positive Interim Data from Phase 1 FOCUS Trial of Investigational Gene Therapy GT005https://modernod.com/news/gyroscope-therapeutics-announces-positive-interim-data-from-phase-1-focus-trial-of-investigational-gene-therapy-gt005/2478865/Gyroscope Therapeutics announced positive interim safety, protein expression and biomarker data from the ongoing open-label phase 1/2 FOCUS clinical trial of its investigational gene therapy, GT005, in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Inte
- Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%https://modernod.com/news/akorn-receives-fda-approval-for-loteprednol-etabonate-ophthalmic-gel-0-5/2478864/Akorn announced that it received approval of its abbreviated new drug application (ANDA) from the FDA for loteprednol etabonate ophthalmic gel, 0.5%, which is indicated for the treatment of postoperative inflammation and pain following ocular surgery. “We are excited to launch yet an
- Genentech: New Phase 3 Data Show Faricimab the First Investigational Injectable Eye Medicine to Extend Time Between Treatment to Up to 4 Monthshttps://modernod.com/news/new-phase-3-data-show-genentechs-faricimab-is-the-first-investigational-injectable-eye-medicine-to-extend-time-between-treatment-to-up-to-4-months/2478862/Genentech announced detailed results from four phase 3 studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The studies consistently showed that faricimab, given at intervals of up